Skip to main content

Table 2 Maternal and neonatal outcomes after FET in women with NC, HRT and OI group

From: Increased risk of maternal and neonatal complications in hormone replacement therapy cycles in frozen embryo transfer

 

NC

HRT

OI

P-value

Maternal outcomes

 HDP, n. (%)

166 (3.5)a

130 (7.9)c

24 (4.6)

< 0.001*

 GDM, n. (%)

247 (5.2)b

106 (6.5)

39 (7.5)

0.030*

 Placenta previa, n. (%)

47 (1.0)

24 (1.5)

6 (1.2)

0.299

 Oligohydramnios, n. (%)

61 (1.3)

17 (1.0)

9 (1.7)

0.437

Neonatal outcomes

 Gestational age (weeks)

   < 32

39 (0.6)b

18 (1.1)

8 (1.5)

0.023*

  32–36+ 6

188 (4.0)a,b

111 (6.8)

32 (6.2)

< 0.001*

   ≥ 37

4510 (95.4)a,b

1513 (92.1)

477 (92.3)

< 0.001*

  LBW, n. (%)

130 (2.8)a

74 (4.5)

19 (3.7)

0.002*

  SGA, n. (%)

165 (3.5)

48 (2.9)

26 (5.0)

0.073

  LGA, n. (%)

1104 (23.4)

430 (26.2)c

114 (22.1)

0.040*

 Gender of neonates n. (%)

   

0.890

  Male, n. (%)

2500 (52.9)

863 (52.6)

278 (53.8)

 

  Female, n. (%)

2227 (47.1)

779 (47.4)

239 (46.2)

 
  1. FET frozen embryo transfer, NC natural cycle, HRT hormone replacement therapy, OI ovulation induction, HDP hypertensive disorders of pregnancy, GDM gestational diabetes mellitus, LBW low birth weight, SGA small for gestational age, LGA large for gestational age
  2. *There were significant differences among the three groups
  3. a There were significant differences between NC and HRT group
  4. b There were significant differences between NC and OI group
  5. c There were significant differences between HRT and OI group